A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years - NCT06810505

Summary

Status & Type
    Key Dates
      Lead Sponsor

      Conditions
        Interventions
          Arm Group Labels
            Primary Outcomes
              GreyB © 2025 Elixir. All rights reserved.